Koyama et al., Biochim Biophys. Acta, vol. 617(2) pp. 218-224, 1980.* |
Nagano et al, Bull. Chem. Soc. Jpn., vol. 69(7) pp. 2071-2078, 1996.* |
Mu et al., J. Org. Chem., vol. 61(23) pp. 8010-8015, 1996.* |
Sen et al., J. Org. Chem., vol. 62(11) pp. 3529-3536, 1997.* |
Dawe et al., Biochemistry, vol. 36(40) pp 12036-12044, 1997.* |
Burke, et al., Inhibition of Pancreatic Cancer Growth by the Dietary Isoprenoids Farnesol and Geraniol, Lipids, vol. 32, No. 2, pp. 151-156 (1997). |
Cox, et al., Analysis of Ras Protein Expression in Mammalian Cells, Methods in Enzymology, vol. 255, pp. 195-220 (1995). |
Cox, et al., Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?, Biochimica et Biophysica Acta, vol. 1333, pp. F51-F71 (1997). |
Cox, et al., Specific Isoprenoid Modification Is Required for Function of Normal, but Not Oncogenic, Ras Protein, Mol. Cell. Biol., vol. 126, pp. 2606-2615 (1992). |
Dawe, et al., Novel Modifications to the Farnesyl Moiety of the a-Factor Lipopeptide Pheromone from Saccharomyces cerevisiae: A Role for Isoprene Modifications in Ligand Presentation, Biochemistry, vol. 36, pp. 12036-12044 (1997). |
Dolence, et al., A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 5008-5011 (1995). |
Finder, et al., Inhibition of Protein Geranylgeranylation Causes a Superinduction of Nitric-oxide Synthase-2 by Interleukin-1β in Vascular Smooth Muscle Cells, J. Biol. Chem., vol. 272, No. 21, pp. 13484-13488 (1997). |
Gibbs, et al., A Steroselective Palladium/Copper-Catalyzed route to isoprenoids: Synthesis and Biological Evaluation of 13-Methylidenefarnesyl Diphosphate. J. Org. Chem., vol. 60, No. 24, pp. 7821-7829 (1995). |
Kohl, et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nature Med., vol. 1, No. 8, pp. 792-797 (1995). |
Leonard, Ras Farnesyltransferase: A New Therapeutic Target, J. Med. Chem., vol. 40, No. 19, pp. 2971-2990 (1997). |
Lowy, et al., Rational cancer therapy, Nature Med., 1:8, pp. 747-748 (1995). |
McGuire, et al., Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation, J. Biol. Chem., vol. 271, No. 44, pp. 27401-27407 (1996). |
Mu, et al., Cuprate-Mediated Synthesis and Biological Evaluation of Cyclo-propyl- and tert-Butylfarnesyl Diphospate Analogs, J. Org. Chem., vol. 61, pp. 8010-8015 (1996). |
Roullet, et al., Farnesol Inhibits L-type Ca2+ Channels in Vascular Smooth Muscle Cells, J. Biol. Chem., vol. 272, No. 15, pp. 32240-32246 (1997). |
Scholten, et al., Inhibitors of Farnesyl:Protein Transferase—A Possible Cancer Chemotherapeutic, Bioorg. Med. Chem., vol. 4, No. 9, pp. 1537-1543 (1996). |
Yokoyama, et al., Differential Prenyl Pyrophosphate Binding to Mammalian Protein Geranylgeranyltransferase-I and Protein Farnesyltransferase and Its Consequences on the Specifity of Protein Prenylation, J. Biol. Chem., vol. 272, No. 7, pp. 3944-3952 (1997). |